查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715854

代谢体学市场（按成分、适应症、应用和最终用户划分）—2025-2030 年全球预测

Metabolomics Market by Component, Indication, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计代谢体学市场在 2024 年的价值将达到 30.5 亿美元，在 2025 年将达到 33.9 亿美元，复合年增长率为 11.38%，到 2030 年将达到 58.3 亿美元。

主要市场统计数据
基准年2024年 30.5亿美元
预计2025年 33.9亿美元
预测年份 2030 58.3亿美元
复合年增长率（%） 11.38%

代谢体学是一门快速发展的学科，它彻底改变了我们理解生物过程和疾病机制的方式。在当今竞争激烈、科学研究日趋激烈的环境下，受分析技术进步、大量「体学」数据涌入以及个人化医疗日益受到重视的推动，该领域正在经历前所未有的增长。该报告提供了详细的分析，融合了市场动态、技术突破和创新方法，为相关人员提供了对当前趋势和未来前景的深入了解。

该学科围绕着生物系统内代谢物的大规模研究，是药物发现、疾病诊断和环境安全评估等多个领域研究的基石。研究人员和决策者现在认识到，弥合传统生化检测与现代数据丰富的环境之间的差距可以带来推动创新的改变游戏规则的见解。在探索这一广阔领域时，读者将清楚地了解为成功设定新基准并为次世代应用程式铺平道路的科学进步和市场驱动力。

在强劲需求和成功融入学术、临床和工业框架的推动下，该领域正在重塑范式。该报告不仅概述了历史发展和当前市场情景，还概述了可能对研究成果和商业策略产生重大影响的未来发展轨迹。透过密切关注不断发展的趋势，您可以了解代谢体学如何弥合理论研究与实际应用之间的差距，成为追求创新和卓越的行业的重要资源。

改变代谢代谢体学格局的变革

代谢体学的发展经历了变革性的变化，正以前所未有的速度重塑竞争格局。一个关键的变化是最尖端科技和先进分析平台的快速整合，从而实现高通量和灵敏的代谢物检测。这种演变主要由检测工具的创新所推动，例如质谱、核磁共振光谱和表面质谱，这些工具正变得越来越复杂并融入尖端的工作流程中。

随着传统调查方法被更强大的技术主导方法所取代，行业专家正在观察市场动态的重大转变。不断变化的法规环境、对遗传基础的更好理解以及公共和私营部门之间的合作努力共同推动了该领域的发展。这些发展正在鼓励采用更灵活、以数据为中心的方法，不仅可以提高诊断的准确性，还可以加速药物倡议。

随着新平台和软体创新的出现，生物资讯学工具和服务处于促进数据分析和解释的前沿。资料库和服务的不断改进使得准确解释曾经被认为几乎不可能的复杂生化资料成为可能。透过利用这些趋势，行业领导者不仅可以更好地利用科学突破，还可以将技术创新转化为商业性机会。

此外，随着个人化医疗的经济和社会影响不断扩大，对研究的持续投资和由此产生的技术进步使代谢体学成为更广泛的医疗保健转型的重要支柱。市场格局的这种动态变化使得相关人员必须投资于持续学习并采用整合技术和临床见解的方法。

揭示代谢体学中的关键细分见解

代谢体学的细分格局复杂而微妙，提供了超越传统界限的市场动态的多方面视角。首先，根据组件进行细分时，市场被分为生物资讯学工具和服务以及代谢体学仪器进行分析。生物资讯学领域进一步分为专用服务和广泛的工具和资料库，而代谢组学分析仪器类别则更深入，区分检测和分离工具。检测工具对于准确的定量和定性分析至关重要，分为质谱、核磁共振波谱和表面质谱等技术。同样重要的是分离样品所必需的分离工具，其中包括毛细管电泳、气相层析法、高效液相层析和超高效液相层析等多种策略。

另一层细分是适应症方面，我们研究心血管、代谢、神经学、肿瘤学等各种疾病的市场。这种分类不仅突显了应用的多样性，而且强调了代谢组学分析策略在解决多器官疾病方面的相关性。每种适应症都将成为治疗和诊断创新的基准，确保代谢体学的应用得到改进并发挥最大作用。

细分还可以透过基于应用程式的洞察进行扩展。该领域的研究受到生物标记发现、药物发现、环境科学、营养基因组学、个人化医疗和毒性测试等关键应用的推动。生物标记的发现重点关注癌症和神经系统生物标誌物，它们为早期检测和成功的干预策略提供了重要的催化剂。同样，药物发现活动正在加强代谢途径探索和标靶识别，以支持合理的化合物开发和重新定位策略。在环境科学领域，研究重点是农药残留和水质，而营养基因体学研究则关注心血管健康和肥胖问题。此外，个人化医疗利用基因组研究和治疗监测来根据患者的个别情况制定干预措施。这些应用中的每一个都在塑造市场趋势的同时满足重要的科学和商业性需求方面发挥着独特的作用。

最后，透过根据学术研究机构、合约研究组织、製药公司、生物技术公司等不同群体对市场进行分类，最终用户细分提供了有价值的见解。这种细分对于理解各相关人员如何利用代谢体学来推动创新并在研究和工业业务中获得竞争优势至关重要。综合起来，这种多层次的细分提供了一幅全面的图景，展示了不同的元素如何结合在一起，创造一个满足动态和不断变化的需求的生态系统。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 提高公众和政府代谢体学在医疗保健中的重要性的认识
      • 全球范围内慢性病和文明病的发生率正在增加。
      • 代谢体学组学质谱和核磁共振技术的进展
    • 限制因素
      • 代谢体学研究设备高成本
    • 机会
      • 个人化医疗需求的不断增长和代谢体学技术的进步
      • 拓展代谢体学在法医学的应用，获得更准确、可靠的毒理学结果
    • 任务
      • 代谢体学研究中缺乏训练有素的专家，资料整合困难
  • 市场区隔分析
    • 组成：毛细管电泳在分离少量复杂混合物中扮演重要角色。
    • 适应症：对个人化医疗日益增长的兴趣将推动代谢体学的需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章代谢体学市场（依成分）

  • 生物资讯学工具和服务
    • 生物资讯服务
    • 生物资讯工具和资料库
  • 代谢体学学仪器
    • 发现工具
      • 质谱法
      • 核磁共振波谱
      • 基于表面的质谱法
    • 隔离工具
      • 毛细管电泳
      • 气相层析法
      • 高效液相层析
      • 超高效液相层析

第七章代谢体学市场（按适应症）

  • 心血管疾病
  • 代谢紊乱
  • 神经系统疾病
  • 肿瘤疾病

第 8 章代谢体学市场（按应用）

  • 生物标记发现
    • 癌症生物标记
    • 神经系统生物标记
  • 药物研发
    • 代谢途径
    • 目标识别
  • 环境科学
    • 农药残留分析
    • 水质分析
  • 营养基因体学
    • 心血管健康
    • 肥胖调查
  • 个人化医疗
    • 基因组学研究
    • 治疗监测
  • 毒性测试

第九章代谢体学市场（按最终用户）

  • 学术研究所
  • 合约研究组织
  • 製药和生物技术公司

第 10 章：美洲代谢体学市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太代谢代谢体学市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲代谢体学市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Afekta Technologies Ltd.
  • BASF SE
  • Bio-Rad Laboratories, Inc.
  • Biocrates Life Science AG
  • Bruker Corporation
  • Clinical Microbiomics A/S
  • Danaher Corporation
  • DNA Xperts Private Limited
  • General Metabolics
  • Hitachi High-Tech Corporation
  • Human Metabolome Technologies Inc.
  • JASCO Corporation
  • Kore Technology Limited
  • LECO Corporation
  • Merck KGaA
  • Metabolon, Inc.
  • Shimadzu Corporation
  • Techcomp Europe Ltd
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-50124643847C

The Metabolomics Market was valued at USD 3.05 billion in 2024 and is projected to grow to USD 3.39 billion in 2025, with a CAGR of 11.38%, reaching USD 5.83 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.05 billion
Estimated Year [2025] USD 3.39 billion
Forecast Year [2030] USD 5.83 billion
CAGR (%) 11.38%

Metabolomics stands out as a rapidly evolving discipline that has transformed the way we comprehend biological processes and disease mechanisms. In today's competitive and scientifically intense environment, the field is witnessing unprecedented growth, driven by advances in analytical technologies, the influx of massive 'omics' data, and an increased prioritization of personalized healthcare approaches. This report provides an in-depth analysis that amalgamates market dynamics, technological breakthroughs, and innovative methodologies to offer stakeholders a robust understanding of the prevailing trends and future outlook.

The discipline, which revolves around the large-scale study of metabolites within biological systems, has become a cornerstone for research in multiple domains, including drug discovery, disease diagnostics, and environmental safety assessments. Researchers and decision-makers now recognize that bridging the gap between traditional biochemical assays and the modern data-rich environment can unlock transformative insights that fuel innovation. As we explore this expansive landscape, readers will gain clarity on both the scientific advancements and market drivers that are setting new benchmarks for success and paving the way for next-generation applications.

Driven by robust demand and successful integration into academic, clinical, and industrial frameworks, the field is reshaping its paradigms. This report lays down not only the historical development and current market scenario but also delineates future trajectories that could significantly impact both research outcomes and commercial strategies. With a keen eye on evolving trends, one can appreciate how metabolic profiling is bridging theoretical research with practical, real-world applications, making metabolomics an indispensable resource for industries seeking to innovate and excel.

Transformative Shifts Reshaping the Metabolomics Landscape

The evolution of metabolomics has witnessed transformative shifts that are reshaping the competitive landscape at an unprecedented pace. One key change is the rapid integration of cutting-edge technologies and advanced analytical platforms that enable high-throughput and highly sensitive metabolite detection. This evolution is driven largely by emerging innovations in detection tools, such as mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis, which are increasingly refined and integrated into state-of-the-art workflows.

Industry experts have observed significant shifts in market dynamics as traditional research methods are replaced by more robust, technology-driven approaches. Changing regulatory milieus, an increased understanding of genetic underpinnings, and collaborative efforts between the public and private sectors have collectively propelled the field. These developments encourage a more agile, data-centric approach that not only enhances diagnostic accuracy but also accelerates drug discovery initiatives.

With the advent of new platforms and software innovations, bioinformatics tools and services are now at the forefront of facilitating data analysis and interpretation. The continuous refinement of databases and services is enabling precise interpretations of complex biochemical data, which was once considered near-impossible. As industry leaders harness these trends, they are poised to not only capitalize on scientific breakthroughs but also convert technological innovations into commercial opportunities.

Furthermore, as the economic and societal implications of personalized medicine continue to grow, ongoing investments in research and the resultant technological advancements position metabolomics as a key pillar in the broader narrative of healthcare transformation. This dynamic reformation in the market landscape is making it imperative for stakeholders to invest in continuous learning and embrace integrated approaches that unite technology with clinical insights.

Unveiling Key Segmentation Insights in Metabolomics

The segmentation landscape in metabolomics is both complex and nuanced, providing a multi-dimensional view into market dynamics that transcend traditional boundaries. Initially, when exploring segmentation based on component, the market is analyzed by dividing it into bioinformatics tools and services along with metabolomic instruments. The bioinformatics domain is further classified into dedicated services and a broad array of tools and databases, while the category of metabolomic instruments is delved into depth by distinguishing between detection tools and separation tools. Detection tools form a pivotal component in achieving precise quantitative and qualitative analyses, being subdivided into technologies such as mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis. Equally important are separation tools that are critical for sample resolution, which in this context, include a range of strategies from capillary electrophoresis, gas chromatography, high-performance liquid chromatography, to ultra performance liquid chromatography.

Another layer of segmentation looks at the indication side, where the market is studied across various disorders including cardiovascular, metabolic, neurological, and oncological conditions. This categorization not only highlights the diversity of applications but also underscores the relevance of metabolomic strategies in addressing multi-systemic disorders. Each indication serves as a benchmark for innovation in therapeutic and diagnostic modalities, ensuring that the application of metabolomics is refined and targeted for maximum impact.

Segmentation also unfolds through application-based insights. In this realm, research is driven by major applications such as biomarker discovery, drug discovery, environmental science, nutrigenomics, personalized medicine, and toxicology testing. For biomarker discovery, an important focus is cast on both cancer and neurological biomarkers which are critical triggers for early detection and successful intervention strategies. Similarly, drug discovery efforts are enhanced by investigations into metabolic pathways and target identification, which support streamlined compound development and repositioning strategies. In the environmental science segment, analyses concentrate on pesticide residue and water quality, while nutrigenomics studies investigate cardiovascular health alongside obesity research. Moreover, personalized medicine leverages genomic studies and therapeutic monitoring to tailor interventions that align with individual patient profiles. Each of these applications plays a distinct role in molding market trends while fulfilling a critical demand in scientific and commercial arenas.

Finally, end-user segmentation provides invaluable insights by categorizing the market based on distinct groups such as academic research institutes, contract research organizations, and pharmaceutical as well as biotechnology companies. This segmentation is crucial in understanding how different stakeholders leverage metabolomics to drive innovation and competitive advantage in both research and industrial operations. Collectively, this multi-layered segmentation offers an exhaustive view of how various elements combine to create an ecosystem that is both dynamic and responsive to evolving needs.

Based on Component, market is studied across Bioinformatics Tools & Services and Metabolomic Instruments. The Bioinformatics Tools & Services is further studied across Bioinformatics Services and Bioinformatics Tools & Databases. The Metabolomic Instruments is further studied across Detection Tools and Separation Tools. The Detection Tools is further studied across Mass Spectrometry, Nuclear Magnetic Resonance Spectroscopy, and Surface-based Mass Analysis. The Separation Tools is further studied across Capillary Electrophoresis, Gas Chromatography, High-Performance Liquid Chromatography, and Ultra Performance Liquid Chromatography.

Based on Indication, market is studied across Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, and Oncological Disorders.

Based on Application, market is studied across Biomarker Discovery, Drug Discovery, Environmental Science, Nutrigenomics, Personalized Medicine, and Toxicology Testing. The Biomarker Discovery is further studied across Cancer Biomarkers and Neurological Biomarkers. The Drug Discovery is further studied across Metabolic Pathways and Target Identification. The Environmental Science is further studied across Pesticide Residue Analysis and Water Quality Analysis. The Nutrigenomics is further studied across Cardiovascular Health and Obesity Research. The Personalized Medicine is further studied across Genomic Studies and Therapeutic Monitoring.

Based on End-User, market is studied across Academic Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.

Key Regional Insights Illuminating Market Trends

The global landscape of metabolomics presents a rich tapestry of regional variations that offer both challenges and remarkable opportunities. In the Americas, a robust infrastructure combined with strong financial backing and advancing technological ecosystems makes the region a pioneering hub for both innovation and clinical applications. Research facilities and healthcare institutions in this region are particularly adept at integrating novel metabolomic technologies with clinical workflows, thereby spearheading groundbreaking developments across academic and industrial spheres.

In Europe, Middle East and Africa, a diverse economic architecture underpins the market dynamics. The integration of legacy systems with modern technologies in these regions is resulting in innovative methodological adaptations that cater to both established and emerging healthcare needs. This region is characterized by a unique blend of regulatory support, private investments, and public funding initiatives designed to nurture research excellence and industrial competitiveness. The evolving policies and strategic collaborations between various institutions have gradually cemented this region as a significant player in the global metabolomics domain.

Asia-Pacific is experiencing a rapid surge in research and industrial activities related to metabolomics, fueled by increased investment in biotechnology, an expanding pool of skilled professionals, and a burgeoning consumer market focused on personalized solutions. The accelerated pace of technological adaptation combined with pragmatic government policies has positioned the region as a fertile ground for innovation. These regional trends exemplify how a dynamic interplay between economic resilience and technological advancements can catalyze market growth and foster collaborative synergies across nations.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Company Insights and Market Innovators

Within the competitive sphere of metabolomics, a host of leading companies continue to forge pathways that drive innovation and set industry standards. Esteemed corporations, including Afekta Technologies Ltd. and BASF SE, leverage deep scientific expertise and robust market strategies to catalyze growth in emerging segments. Pioneering roles are also observed for organizations such as Bio-Rad Laboratories, Inc. and Biocrates Life Science AG, which are at the forefront of refining analytical methods and digital data integration.

Industry behemoths like Bruker Corporation, Danaher Corporation, and Hitachi High-Tech Corporation have significantly contributed to advancing the quality and precision of metabolomic instruments. These companies, with their sophisticated technologies and comprehensive service portfolios, have managed to bridge the gap between foundational scientific research and commercial usability. Equally notable are specialized players such as Clinical Microbiomics A/S and DNA Xperts Private Limited, each demonstrating singular competencies in niche segments that drive both innovation and market penetration. The contributions of General Metabolics and Human Metabolome Technologies Inc. cannot be understated as they push the technological envelope further, ensuring that detection and separation methodologies remain at the industry's cutting edge.

Collaborative ventures with firms like JASCO Corporation, Kore Technology Limited, LECO Corporation, and Merck KGaA have resulted in trailblazing product lines that not only enhance laboratory performance but also support data analytics for better decision making. The integration of these technological solutions with a focus on comprehensive customer service is reflected in the strategic moves by Metabolon, Inc., Shimadzu Corporation, Techcomp Europe Ltd, Thermo Fisher Scientific Inc., and Waters Corporation. Their continuous innovation cycles and solid market strategies have collectively shaped an ecosystem where scientific exploration meets market viability in a seamless and synergistic manner.

These companies are setting benchmarks in quality and innovation while fostering competitive collaborations that stimulate market awareness and technological excellence. Their roles are not limited to providing advanced technologies but extend into offering holistic service models that nurture research capabilities and drive the overall evolution of the metabolomics sector.

The report delves into recent significant developments in the Metabolomics Market, highlighting leading vendors and their innovative profiles. These include Afekta Technologies Ltd., BASF SE, Bio-Rad Laboratories, Inc., Biocrates Life Science AG, Bruker Corporation, Clinical Microbiomics A/S, Danaher Corporation, DNA Xperts Private Limited, General Metabolics, Hitachi High-Tech Corporation, Human Metabolome Technologies Inc., JASCO Corporation, Kore Technology Limited, LECO Corporation, Merck KGaA, Metabolon, Inc., Shimadzu Corporation, Techcomp Europe Ltd, Thermo Fisher Scientific Inc., and Waters Corporation. Actionable Recommendations for Industry Leaders

Decision-makers and industry leaders are encouraged to adopt a forward-thinking strategy to leverage the inherent opportunities within the metabolomics market. Foremost, it is imperative to invest in state-of-the-art technologies and research and development initiatives that continuously enhance detection precision and analytical reliability. Building cross-functional collaborations between academic, clinical, and industry partners can not only foster innovation but also streamline the translation of metabolomic insights into tangible, marketable applications.

In addition, aligning corporate strategies with evolving regulatory standards and fostering a culture of continuous improvement is essential. Leaders should prioritize the integration of robust quality management systems and leverage digital transformation across their operational models. This not only enhances process efficiency but also improves the overall quality of research outputs and commercial products.

It is also advisable to diversify portfolio investments by exploring various segmentation engines such as component-based differentiation, indication for targeted therapies, and application-specific research. This diversified approach mitigates risk while tapping into niche markets that are often characterized by higher growth potential. Industry leaders should also consider how emerging trends in personalized medicine, nanotechnology, and artificial intelligence can be assimilated into existing frameworks, thus driving competitive advantage.

Furthermore, companies are encouraged to cultivate an ecosystem that prioritizes skill development and talent acquisition. Strategic hires and continued professional development programs ensure that the workforce remains adept at handling the latest technological innovations and adept at innovators' challenges. Strengthening research capabilities through targeted funding and appropriate resource allocation not only bolsters overall market positioning but also enhances the practical applicability of metabolomic insights.

Finally, maintaining agility in formulation and execution of commercial strategies is key. Organizations must continuously monitor global trends and market responses, ensuring that they remain adaptive to changes in consumer behavior and technological evolution. Moving beyond conventional approaches and embracing next-generation insights will undoubtedly reinforce market leadership and pave the way for sustained growth in the dynamically evolving field of metabolomics.

Conclusion: Synthesis of Metabolomics Market Trends

In summarizing the expansive landscape of metabolomics, several pivotal themes emerge that underline the evolution and future trajectory of this dynamic field. The integration of advanced analytical instruments and sophisticated bioinformatics tools has not only redefined research methodologies but also enabled a more nuanced understanding of complex metabolic processes. This transformative shift is driving significant investments in both technology and human capital, thereby laying a strong foundation for the future growth of the market.

The detailed segmentation analysis underscores how a multi-faceted approach - involving components, indications, applications, and end-user insights - interweaves to create a resilient and responsive market ecosystem. Each segmentation parameter reveals layers of opportunity, whether it is harnessing the power of mass spectrometry and nuclear magnetic resonance technologies or addressing critical healthcare challenges such as cardiovascular and metabolic disorders.

Regional factors also continue to play a critical role in shaping market dynamics. The Americas, with its advanced infrastructure; Europe, Middle East and Africa, with its blend of tradition and innovation; and Asia-Pacific's rapid ascent in technology adoption together paint a picture of a truly global evolution in the domain of metabolomics. Key players in the market, ranging from industry giants to specialized firms, are collectively propelling this revolution through innovative solutions and strategic operational excellence.

This synthesis of market trends and insights emphasizes that metabolomics is not just a scientific field but a transformative conduit that bridges research and real-world clinical applications. As industries evolve and new challenges emerge, the ability to adapt, innovate, and integrate will determine long-term success in capitalizing on this robust market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing public and government awareness regarding the importance of metabolomics in healthcare
      • 5.1.1.2. Rising prevalence of chronic and lifestyle-related diseases across the globe
      • 5.1.1.3. Advancements in mass spectrometry and nuclear magnetic resonance technologies for metabolomics
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with metabolomics research instruments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for personalized medicine combined with advancements in metabolomics technologies
      • 5.1.3.2. Increasing application of metabolomics in forensic science for more accurate and reliable toxicology results
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of trained professionals and data integration difficulties in metabolomics research
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Capillary electrophoresis plays a crucial role in resolving small volumes of complex mixtures
    • 5.2.2. Indication: Rising emphasis on personalized medicine accelerates demand for metabolomics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Metabolomics Market, by Component

  • 6.1. Introduction
  • 6.2. Bioinformatics Tools & Services
    • 6.2.1. Bioinformatics Services
    • 6.2.2. Bioinformatics Tools & Databases
  • 6.3. Metabolomic Instruments
    • 6.3.1. Detection Tools
      • 6.3.1.1. Mass Spectrometry
      • 6.3.1.2. Nuclear Magnetic Resonance Spectroscopy
      • 6.3.1.3. Surface-based Mass Analysis
    • 6.3.2. Separation Tools
      • 6.3.2.1. Capillary Electrophoresis
      • 6.3.2.2. Gas Chromatography
      • 6.3.2.3. High-Performance Liquid Chromatography
      • 6.3.2.4. Ultra Performance Liquid Chromatography

7. Metabolomics Market, by Indication

  • 7.1. Introduction
  • 7.2. Cardiovascular Disorders
  • 7.3. Metabolic Disorders
  • 7.4. Neurological Disorders
  • 7.5. Oncological Disorders

8. Metabolomics Market, by Application

  • 8.1. Introduction
  • 8.2. Biomarker Discovery
    • 8.2.1. Cancer Biomarkers
    • 8.2.2. Neurological Biomarkers
  • 8.3. Drug Discovery
    • 8.3.1. Metabolic Pathways
    • 8.3.2. Target Identification
  • 8.4. Environmental Science
    • 8.4.1. Pesticide Residue Analysis
    • 8.4.2. Water Quality Analysis
  • 8.5. Nutrigenomics
    • 8.5.1. Cardiovascular Health
    • 8.5.2. Obesity Research
  • 8.6. Personalized Medicine
    • 8.6.1. Genomic Studies
    • 8.6.2. Therapeutic Monitoring
  • 8.7. Toxicology Testing

9. Metabolomics Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic Research Institutes
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Metabolomics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Metabolomics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Metabolomics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. TNAU partners with start-ups for pioneering metabolomics research
    • 13.3.2. Trinity Biotech announces acquisition of Metabolomics Diagnostics
    • 13.3.3. Metabolon secures USD 60 million credit facility to accelerate growth and innovation in metabolomics
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Afekta Technologies Ltd.
  • 2. BASF SE
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Biocrates Life Science AG
  • 5. Bruker Corporation
  • 6. Clinical Microbiomics A/S
  • 7. Danaher Corporation
  • 8. DNA Xperts Private Limited
  • 9. General Metabolics
  • 10. Hitachi High-Tech Corporation
  • 11. Human Metabolome Technologies Inc.
  • 12. JASCO Corporation
  • 13. Kore Technology Limited
  • 14. LECO Corporation
  • 15. Merck KGaA
  • 16. Metabolon, Inc.
  • 17. Shimadzu Corporation
  • 18. Techcomp Europe Ltd
  • 19. Thermo Fisher Scientific Inc.
  • 20. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. METABOLOMICS MARKET MULTI-CURRENCY
  • FIGURE 2. METABOLOMICS MARKET MULTI-LANGUAGE
  • FIGURE 3. METABOLOMICS MARKET RESEARCH PROCESS
  • FIGURE 4. METABOLOMICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL METABOLOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES METABOLOMICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES METABOLOMICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. METABOLOMICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. METABOLOMICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. METABOLOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL METABOLOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. METABOLOMICS MARKET DYNAMICS
  • TABLE 7. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES METABOLOMICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 174. CHINA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 175. CHINA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 187. INDIA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 188. INDIA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 200. INDONESIA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 201. INDONESIA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 213. JAPAN METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 214. JAPAN METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 226. MALAYSIA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 227. MALAYSIA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 240. PHILIPPINES METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 252. SINGAPORE METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 253. SINGAPORE METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 264. SOUTH KOREA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 266. SOUTH KOREA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. TAIWAN METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 269. TAIWAN METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 275. TAIWAN METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 276. TAIWAN METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 277. TAIWAN METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 278. TAIWAN METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 279. TAIWAN METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 280. THAILAND METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 281. THAILAND METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 282. THAILAND METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 288. THAILAND METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 289. THAILAND METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 290. THAILAND METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 291. THAILAND METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 292. THAILAND METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. VIETNAM METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 294. VIETNAM METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 295. VIETNAM METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 301. VIETNAM METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 302. VIETNAM METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 303. VIETNAM METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 304. VIETNAM METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 305. VIETNAM METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 320. DENMARK METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 321. DENMARK METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 322. DENMARK METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 323. DENMARK METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 324. DENMARK METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 325. DENMARK METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 326. DENMARK METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. DENMARK METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 328. DENMARK METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 329. DENMARK METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 330. DENMARK METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 331. DENMARK METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 332. DENMARK METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 333. EGYPT METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 334. EGYPT METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 335. EGYPT METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 336. EGYPT METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 337. EGYPT METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 338. EGYPT METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 339. EGYPT METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 340. EGYPT METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 341. EGYPT METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 342. EGYPT METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2030 (USD MILLION)
  • TABLE 343. EGYPT METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2030 (USD MILLION)
  • TABLE 344. EGYPT METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
  • TABLE 345. EGYPT METABOLOMICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 346. FINLAND METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 347. FINLAND METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 348. FINLAND METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 349. FINLAND METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 350. FINLAND METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2030 (USD MILLION)
  • TABLE 351. FINLAND METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 352. FINLAND METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 353. FINLAND METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 354. FINLAND METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MI